PeloNews Nov/Dec 2018

pelobiotech

PeloNews with focus on cells and media

PELONEWS WITH FOCUS ON CELLS & MEDIA

PELOBiotech Newsletter Nov/Dec. 2018

Welcome dear Scientist,

do you know how to avoid budgetary cutbacks? Store your

money in liquid nitrogen We have heard, you have a hard time

to lock your budget. So be smart and order now

cells&media you might need anyway.

Or do you look for something special? Smoke Cells? Aged

Mouse Cells? Diabetic Mouse cells? Monkey cells? Industrial

Lots? Some cells I can offer with a Special Discount Just give

us a call and we can see what we can do. See here our list.

Profit from one of the worldwide biggest cell portfolio

worldwide on Human tagged, Human & Animal cells and

click for list here. Cheers,

Christiane Büchsel

Editor in Chief PELONews

Great meeting at

EACR in Berlin

Please note due to the holiday

season our delivery times:

last deliveries

CW 51 (Dec 19, 2018; based upon

stock) No deliveries CW52:

Please contact us in between in

urgent matters, we are always

happy and willing to help.

“Dreams don´t work

unless you do.“

John C. Maxwell, US Author

Content

Meet us at IZB

Holiday Delivery

Dates

NEW Products

NEW : Syntrix

NEW: Native Coat

CoSeedis

Antibodies

Primary cells

Featured Fields


3D

Want to know

more about PELO-

Biotech? Visit our

site and find out

about our Special-

Cells&Media Offers.

You like what you see? Sign up for PELO-

News now at www.pelobiotech.com or just

fill out the following form here.

And if you are already a fan

-> Join PeloClub here and save every time

you order.




Kidney

ECM

Cancer

Primary Cells


PELONews

Relevance of Kidney Organoids

Kidney organoids are relevant from several perspectives, including modelling of kidney disease and injury. Commonly-used

in vitro two-dimensional cell (2D) models are limited because cells behave differently in a 2D configuration

and cannot constitute in vivo-relevant cell-cell interactions.[1] Besides, contemporary in vivo animal models

often fail to represent human diseases due to species-species differences.[2] Modelling diseases using organoids

surpasses these problems. Stem cells from patients with a certain disease can be grown to organoids, which can

experimentally be manipulated in each disease context. Gut organoids are currently the best-established organoid

disease model and are already used in practice to model cystic fibrosis. In most cystic fibrosis patients, a dysfunctional

CFTR gene causes improper fluid

transport along the gut epithelium, which expresses

in abnormally thick and sticky

mucus.[3] CFTR is therefore important in fluid

transport in the gut, which could be

observed by patient gut organoids swelling

less than control gut organoids,[4] an

observation in parallel with the disease phenotype.

Kidney organoids have also

been shown to be relevant in modelling acute

kidney disease, because in vivo-

relevant biomarkers of kidney and DNA damage

show expression in organoids after

injury infliction. It has been shown that, after

treatment of kidney organoids with

antibiotic gentamicin or anti-cancer drug cisplatin,

organoid cells showed expressi- on of kidney injury marker 1.[5]

Organoids can also be used to screen

for efficacy and safety of potentially diseasecuring

drugs. Drug development cur-

rently experiences that 66% and 30% of all

preclinically validated drugs fail to en-

ter the next developmental stage from phase

II and phase III, respectively.[6] This

phenomenon illustrates the huge gap between

preclinical drug validation and success

of these drugs in the clinic, which exists because

the simple two-dimensional in

vitro cell models often do not resemble the

much more complex in vivo patholo-

gies.[2] Large-scale use of organoid systems

in drug screening might bridge the gap

between pre-clinical validation and use of the

drug in the clinic, as they are consi-

dered to more closely resemble the in vivo

situation than two-dimensional cell

cultures.[11, 7] Drug screens employing organoid

systems have already proven

successful. For example, Huang et al. performed

screening of candidate drugs to treat pancreatic cancer on organoids derived from patient stem cells, and

found that the organoids responded better than other candidate drugs to UNC1999, an inhibitor of epigenetic regulator

H3K27me3.[8] Also from the perspective of safety, kidney organoids would be a useful tool in drug nephrotoxicity

screenings. Compared to all other cell types, kidney cells are especially sensitive to toxins, xenobiotics, metabolic

waste products and other potentially harmful compounds,[5, 9] mainly because these compounds become

highly concentrated in renal cells due to extensive water resorption.[12] Nephrotoxicity in kidney cells and subsequent

kidney dysfunction is therefore a common complication of drug administration.[9, 10]

References

Noviocell

Noviocell BV is a highly

innovative biotech

company headquartered

in Oss, The

Netherlands. It focuses

on the development of

the first ever synthetic

solution for 3D cell culturing,

ranging from

organoid growth to

personalized medicine.

Astashkina, A. and D.W. Grainger, Critical analysis of 3-D organoid in vitro cell culture models for

high-throughput drug candidate toxicity assessments. Adv Drug Deliv Rev, 2014. 69-70: p. 1-18.

Ranga, A., N. Gjorevski, and M.P. Lutolf, Drug discovery through stem cell-based organoid models.

Adv Drug Deliv Rev, 2014. 69-70: p. 19-28.

Gardner, J., What you need to know about cystic fibrosis. Nursing, 2007. 37(7): p. 52-5.

Dekkers, J.F., et al., A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat

Med, 2013. 19(7): p. 939-45.

Morizane, R., et al., Nephron organoids derived from human pluripotent stem cells model kidney

development and injury. Nat Biotech, 2015. 33(11): p. 1193-1200.

Au, S.H., et al., Hepatic organoids for microfluidic drug screening. Lab Chip, 2014. 14(17): p. 3290-9.

Wang, S., D. Gao, and Y. Chen, The potential of organoids in urological cancer research. Nat Rev

Urol, 2017. 14(7): p. 401-414.

Huang, L., et al., Ductal pancreatic cancer modeling and drug screening using human pluripotent

stem cell- and patient-derived tumor organoids. Nat Med, 2015. 21(11): p. 1364-71.

Fisel, P., et al., Solute carrier transporter and drug-related nephrotoxicity: the impact of proximal

tubule cell models for preclinical research. Expert Opin Drug Metab Toxicol, 2014. 10(3): p. 395-408.

Kandasamy, K., et al., Prediction of drug-induced nephrotoxicity and injury mechanisms with human

induced pluripotent stem cell-derived cells and machine learning methods. 2015. 5: p. 12337.

Xinaris, C., V. Brizi, and G. Remuzzi, Organoid Models and Applications in Biomedical Research.

Nephron, 2015. 130(3): p. 191-9.

Chuah, J.K. and D. Zink, Stem cell-derived kidney cells and organoids: Recent breakthroughs and

emerging applications. Biotechnol Adv, 2017. 35(2): p. 150-167.


Discover now

Complete ECM Surface Coating Kit

We are pleased to announce the launch of the NativeCoat product line to bring the highly specific

biochemical composition of native cell microenvironment to an in vitro setting.

Coating with cell culture surfaces with NativeCoat results in:





Improved cell attachment

Increased cell viability and proliferation

Enhanced function

Activation of signaling pathways

If you like to know more,

meet East River in November

in Munich – and

enjoy the great view

from the Sky Lounge.

Tickets are limited, to reserve your

spot please sign up via email

katja.schulze@pelobiotech.com

or give her a call:

+49 89 517 286 59-0


PELONews

Fully standardised

3D Micro-Tumour System

abc biopply is introducing a fully standardised 3D micro-tumour system based on its 3D

CoSeedis technology platform. The new 3D CoSeedis Micro-Tumour System –

WiDr offers fully validated protocols and includes all required components to successfully

grow tumour cells into 3D spheroids. It is ideally suited to establish the 3D CoSeedis

technology in your lab and provides easy-to-follow SOPs for:




3D aggregate formation

Maintenance of aggregates for up to 10 weeks

Harvest of grown spheroids

The system allows to monitor tumour growth in real-time and to accurately measure

growth-related effects of treatments.

Furthermore, the system is fully compatible with abc biopply’s organoid histology system.

Adapting the system to other cell types than WiDr can easily be achieved and abc biopply

also offers a customised service to assist.

Contact us for further details and information.

Pic : abc biopply

Try New Gold

Standard for

Primary Cells

Bacteria, yeast, zebrafish,

mice – for decades,

these model organisms

have supported the research

to facilitate breakthrough

discoveries for

human health. But the

gold standard – a human

cell model system – has

been difficult to set-up,

handicapped by genetic

modifications, and prohibitively

expensive.

Through unique antibody

-free cell isolation methods

by our partners at

Cell Systems, primary

human cells can now be

easily incorporated into

your research program

for more relevant and

accurate insights and

validation. Their deep

inventory allows a consistent

cell population

over large-scale studies,

and can be customized

as large lots to supply

the pharmaceutical industry.

Ask your research questions

using the new gold

standard tool: antibodyfree

primary cells.from

our partner Cell Systems.

Also available:


Industrial lots


Pic. Funkoshi

Check out our NEW Products

Anti-SOD1 (ALS-related mutants) Clone : MS785, MS27

New powerful tools to research pathophysiological role of SOD1 mutants in ALS patients

Amyotrophic Lateral Sclerosis (ALS) is a fatal adult-onset neurodegenerative disease. According to

many research results, SOD1 (Cu/Zn superoxide dismutase) is one of the major causative genes of ALS

and SOD1 mutant proteins cause (evoke, lead) ALS through a gain of toxic function.

Wild type SOD1 forms homo dimer. However, it was reported that mutant SOD1 forms the different conformation,

having toxic function by binding to Derlin-1, an ER-associated degradation (ERAD) machinery

protein. Prof. Hidenori Ichijo

and his colleagues developed

two novel rat monoclonal

anti-SOD1 antibodies,

clone MS785 and MS27,

which specifically bind to

conformationally altered

SOD1, not detecting wild

type SOD1 homo-dimer.

Both clones are succeeded

in detecting over 100 SOD1

mutants (Ref.2), please visit

our website for further information

about the list of detectable

SOD1 mutants.

Features



Specific to SOD1 mutants

Application ; IP and IC : Detect SOD1 mutant ELISA : Detect SOD1 mutant Western Blot : Detect SOD1 wild

and mutant type.

Note In denatured condition, MS785 and MS27 detect both wild and mutant type of SOD1


Curious?

Read more and download your flyer.

Ask for our extensive product list of Antibodies: sales@pelobiotech.com


PELONews

Discover our website.

If you need to have a

guided tour, just give us

a call.

We are happy to help

you navigating and getting

the cells and media

you need.

Animal and

Human

Cells List

Just click to get one

of the broadest

portfolios of Animal

and/or Human

Cells here or just

scan the QR-code

to request your personal

copy.

How to

reach us:

If you need any further

assistance or if you like

what you see, tell us:

PELOBiotech GmbH

Klopferspitz 19

82152 Planegg | Germany

Tel.: +49 89 517286 59 0

info@pelobiotech.com

www.pelobiotech.com

HRB 197203

We like your feedback – tell us what you love, don’t like so much and what you

would like to get, please.

Just reply Please update your subscription anytime, as we like to comply to

the new GDPR guidelines.

Dr.Peter Frost

More magazines by this user